We are live on ! Find out more
NTLA icon

Intellia Therapeutics

143 hedge funds and large institutions have $669M invested in Intellia Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 31

44% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 18

14% more capital invested

Capital invested by funds: $589M → $669M (+$80.7M)

5% more funds holding

Funds holding: 136143 (+7)

3.1% more ownership

Funds ownership: 90.23%93.33% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

32% less call options, than puts

Call options by funds: $2.35M | Put options by funds: $3.46M

Holders
143
Holders Change
+7
Holders Change %
+5.15%
% of All Funds
2.82%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
26
Increased
45
Reduced
31
Closed
18
Calls
$2.35M
Puts
$3.46M
Net Calls
-$1.11M
Net Calls Change
-$2.66M
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
76
Millennium Management
New York
$248K -$41.1K -2,952 -15%
ProShare Advisors
77
ProShare Advisors
Maryland
$232K -$25.4K -1,822 -10%
MIM
78
MetLife Investment Management
New Jersey
$231K
SG
79
StoneX Group
New York
$220K -$18.6K -1,335 -8%
HighTower Advisors
80
HighTower Advisors
Illinois
$219K -$31.2K -2,242 -13%
TI
81
Trexquant Investment
Connecticut
$219K +$34.6K +2,490 +20%
Arrowstreet Capital
82
Arrowstreet Capital
Massachusetts
$214K +$203K +14,600 New
MLICM
83
Metropolitan Life Insurance Company (MetLife)
New York
$212K -$17.4K -1,248 -8%
Mirae Asset Global Investments
84
Mirae Asset Global Investments
South Korea
$205K +$47.4K +3,407 +32%
RJFSA
85
Raymond James Financial Services Advisors
Florida
$187K +$177K +12,740 New
D.E. Shaw & Co
86
D.E. Shaw & Co
New York
$185K +$176K +12,625 New
SOMRS
87
State of Michigan Retirement System
Michigan
$179K
I
88
INVST
Indiana
$177K
Legal & General Group
89
Legal & General Group
United Kingdom
$168K +$18.4K +1,326 +13%
AG
90
Aperio Group
California
$168K +$160K +11,470 New
PP
91
Paloma Partners
Connecticut
$167K +$159K +11,414 New
PFGIA
92
Patriot Financial Group Insurance Agency
Massachusetts
$165K +$156K +11,215 New
NIT
93
NumerixS Investment Technologies
British Columbia, Canada
$163K +$34.8K +2,500 +29%
OIA
94
OneDigital Investment Advisors
Kansas
$157K +$149K +10,700 New
MIC
95
Meridian Investment Counsel
California
$147K
CLOS
96
Compagnie Lombard Odier SCmA
Switzerland
$147K +$27.8K +2,000 +25%
Group One Trading
97
Group One Trading
Illinois
$139K -$27.1K -1,949 -17%
Mitsubishi UFJ Asset Management
98
Mitsubishi UFJ Asset Management
Japan
$139K -$598 -43 -0.5%
Victory Capital Management
99
Victory Capital Management
Texas
$125K +$48.6K +3,493 +70%
GT
100
Glenmede Trust
Pennsylvania
$109K +$58.4K +4,200 +125%

NTLA Hedge Fund Activity: Q4 2019 in Review

143 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2019, worth a combined $669M — up 14% from $589M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new NTLA positions and 18 closed out — a net gain of 8 holders — while 45 added to existing stakes and 31 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $10.6M. The largest seller was Ontario Teachers' Pension Plan Board, exiting entirely with an estimated $10.7M sold.

  • 143 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2019, up from 136 in Q3 2019.
  • Funds reported $669M of Intellia Therapeutics stock for Q4 2019, up 14% quarter-over-quarter.
  • 26 funds opened new Intellia Therapeutics positions in Q4 2019 and 18 closed out, a net change of +8 holders.
  • The largest Intellia Therapeutics buyer in Q4 2019 was Fidelity Investments, an estimated $10.6M added.
  • The largest Intellia Therapeutics seller in Q4 2019 was Ontario Teachers' Pension Plan Board, an estimated $10.7M sold.

Based on aggregated 13F filings for Q4 2019.